Phase 1 clinical trial of eneboparatide, a novel PTH receptor 1 agonist

Authors

Institutions

Publication Details

Journal
Endocrine Connections
Published
2025-05-27
DOI
https://doi.org/10.1530/ec-24-0464
Citations
1
Primary Topic
Thyroid and Parathyroid Surgery
Type
article
Field-Weighted Citation Impact
2.01
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Phase 1 clinical trial of eneboparatide, a novel PTH receptor 1 agonist

Mark Sumeray, Michael D. Culler, Michel Ovize, Soraya Allas et al.
1 citations
Endocrine Connections
Thyroid and Parathyroid Surgery
2.01
article

Phase 1 clinical trial of eneboparatide, a novel PTH receptor 1 agonist

Mark Sumeray, Michael D. Culler, Michel Ovize, Soraya Allas, Taha OuldRouis, Michael Mannstadt, Jeroen van de Wetering de Rooij, Stéphane Milano
article en
1 citations

Abstract

No abstract available for this paper.
Endocrine ConnectionsVol. 14(6)
Boston University (US), Harvard University (US), MGH Institute of Health Professions (US), Massachusetts General Hospital (US), Erytech Pharma (France) (FR), PRA Health Sciences (US)
Good health and well-being
Openalex Percentile: Top 15%
Thyroid and Parathyroid Surgery
2.01
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Phase 1 clinical trial of eneboparatide, a novel PTH receptor 1 agonist — Mark Sumeray, Michael D. Culler, et al. · Endocrine Connections (2025) | TGRS Research Map | TGRS